Showing results (1461-1470 of 1,774) with videos related to

Sort By:
Pageof 178
Global Change Biology|May 12, 2026
Climate Change Projected to Double the Richness and Abundance of Soilborne Phytopathogenic Fungi in Southern Maritime AntarcticaKevin K Newsham, Elisabeth M Biersma, Ian S Acuña-Rodríguez, et al.
Epilepsia|March 2, 2021
Prevalence and incidence of epilepsy in Latin America and the Caribbean: A systematic review and meta-analysis of population-based studiesCarlos Alva-Díaz, Alba Navarro-Flores, Oscar Rivera-Torrejon, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 28, 1998
Cerebrospinal fluid levels of transition metals in patients with Parkinson's diseaseF J Jiménez-Jiménez, J A Molina, M V Aguilar, et al.
Actas Dermo-Sifiliograficas|March 25, 2023
Nonvenereal Infections in Spanish Dermatology Clinics: Results of the DIADERM StudyA Pulido-Pérez, M A Descalzo-Gallego, S Arias-Santiago, et al.
Stroke|January 11, 2021
Defining a Target Population to Effectively Test a Neuroprotective DrugMarta Olivé-Gadea, Manuel Requena, Daniel Campos, et al.
Actas Dermo-Sifiliograficas|February 23, 2021
What Proportion of the Caseload at Dermatology Outpatient Clinics in Spain Do Skin Tumors Account for? Results from the DIADERM National Random Sampling ProjectA Martin-Gorgojo, M Á Descalzo-Gallego, S Arias-Santiago, et al.
International Journal of Biological Macromolecules|June 26, 2022
Production of a murine mAb against Bothrops alternatus and B. neuwiedi snake venoms and its use to isolate a thrombin-like serine protease fractionAndreza Alves Belo, Dayane L Naves de Souza, Marcella Nunes de Melo-Braga, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|February 3, 1999
Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's diseaseM V Aguilar, F J Jiménez-Jiménez, J A Molina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2015
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsK Fizazi, T W Flaig, M Stöckle, et al.
Pageof 178